Novo Nordisk stock falls after Morgan Stanley downgrade and patent concerns

Published on 09/12/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock came under pressure on September 11, 2026 after Morgan Stanley cut its rating to Underweight with a price target of USD 40. The shares closed near USD 43, leaving them well below the 52-week high of USD 64.16 and amid growing semaglutide patent worries.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) lost ground as of September 11, 2026, with the New York-listed shares trading around USD 43 after a high-profile downgrade by Morgan Stanley and renewed concerns about its dependence on semaglutide-based drugs.

Morgan Stanley turns bearish on Novo Nordisk

According to GuruFocus, Morgan Stanley analyst Thibault Boutherin downgraded Novo Nordisk from Equal-weight to Underweight on September 11, 2026 and maintained a price target of USD 40.00 for the New York-traded NVO shares.

As Yahoo Finance reports, the bank expects semaglutide to account for about 75 percent of Novo Nordisk’s sales in 2026, leaving the company exposed to a loss of exclusivity beginning in 2031 and raising the risk of generic competition.

The downgrade came even though valuation indicators such as GF Value from GuruFocus suggest the shares could be significantly undervalued, with a GF Value estimate of USD 106.72 compared with a contemporaneous market price of USD 44.01, implying a discount of about 58.8 percent.

Stock trades well below its 52-week high

Per data from Kraken on September 11, 2026, Novo Nordisk’s American depositary shares on the New York Stock Exchange closed at USD 44.02, and during the following session traded around USD 43.02 intraday, a decline of about 2.27 percent from the previous close, with the day’s range between USD 42.99 and USD 43.49 and a market capitalization of roughly USD 190.10 billion as of September 11, 2026.

The same Kraken overview shows that the 52-week range for Novo Nordisk stock stands between USD 35.12 and USD 64.16, meaning the current price near USD 43 is more than USD 20 below the 52-week high and only about USD 8 above the 52-week low, underlining how far the shares have retreated from their peak over the past year.

For investors, this gap between the present level and the high of USD 64.16 is a key reference point: it illustrates that the stock has lost more than 30 percent from its 52-week high, while still remaining markedly above the low of USD 35.12, and suggests a phase of consolidation after a prior rally in GLP-1 obesity and diabetes treatments.

Analyst consensus and other ratings

Despite the Morgan Stanley downgrade, the broader analyst community still takes a more neutral stance. According to MarketBeat data cited on September 12, 2026, Novo Nordisk currently carries a consensus rating of Hold, with four Buy ratings, fourteen Hold ratings and one Sell rating and a consensus price target of USD 64.94.

In the European market, there have also been fresh target changes. As The Globe and Mail relays, Morgan Stanley issued a Sell rating on the London-listed Novo Nordisk line with a price target of DKK 250.00, while HSBC recently maintained a Hold rating and raised its target from DKK 300.00 to DKK 320.00.

A German-language analysis from Trading-Treff notes that the downgrade led to a drop of about 2.8 percent to 278.2 Danish kroner on the Copenhagen exchange and that HSBC’s target increase to 320 Danish kroner came alongside a Hold view, showing a clear split between cautious and more optimistic houses.

Fundamentals and upcoming capital markets day

On the fundamentals side, recent commentary has focused on Novo Nordisk’s heavy reliance on semaglutide and the company’s medium-term guidance. As summarized by Trading-Treff, the guidance for fiscal year 2026 presented in August points to an adjusted revenue and operating profit development between 0 and minus 6 percent at constant exchange rates, signalling that management currently expects flat to moderately declining top-line and earnings compared with the prior year.

According to a recent overview reported by Ad-hoc-news, semaglutide contributed roughly 75 percent of group revenue in 2026, underlining both the blockbuster success of Ozempic and Wegovy and the concentration risk that underpins Morgan Stanley’s cautious stance.

The same Ad-hoc-news report also highlights that Novo Nordisk has been running a substantial buyback program: by September 4, 2026 the company had repurchased about 32 million B shares since early February at an average price of DKK 281.63, representing a transaction volume of approximately DKK 9.0 billion within a twelve-month programme sized at DKK 15.0 billion, which supports earnings per share but ties capital allocation closely to current share levels.

In addition, Novo Nordisk recently recorded a setback in part of its cardiovascular pipeline. As Ad-hoc-news reports, the company halted two Phase III heart failure trials of the antibody ziltivekimab (HERMES and ATHENA) after an independent monitoring committee judged their prospects to be poor, while a third programme, ARTEMIS, continues with data expected in the first half of 2027 and a related non-cash impairment charge flagged for the third quarter of 2026.

Looking ahead, Novo Nordisk plans to address many of these strategic issues at an upcoming investor event. The company’s own investor relations calendar shows that a capital markets day will be held in London on September 21, 2026 from 09:00 to 15:30 BST, giving management an opportunity to explain its medium-term growth strategy, diversification efforts beyond semaglutide and its approach to the looming patent expiries to analysts and institutional investors.

Stock level and investor takeaway

Based on data from Kraken, Novo Nordisk’s American depositary shares on the New York Stock Exchange last traded at USD 43.02 on September 11, 2026, down from a previous close of USD 44.02, with the stock sitting well below its 52-week high of USD 64.16 but clearly above the 52-week low of USD 35.12, and the company’s market capitalization around USD 190.10 billion as of that date.